- Conditions
- Sickle Cell Anemia
- Interventions
- clotrimazole, hydroxyurea
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 10,741
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Vadadustat
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 4 Months to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis
- Interventions
- Aloe Vera Mouthwash, Standard of Care
- Dietary Supplement · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Oak Lawn, Illinois • Park Ridge, Illinois • Milwaukee, Wisconsin
- Conditions
- Neutropenia (Low White Blood Cell Count)
- Interventions
- Filgrastim Hospira (US), US-approved Neupogen®
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- anitocabtagene-autoleucel
- Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Denver, Colorado + 14 more
- Conditions
- Leukemia
- Interventions
- alvocidib, imatinib mesylate
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- prednisone, dexamethasone, doxorubicin, E. coli asparaginase, vincristine, methotrexate, Leucovorin, Asparaginase, cytarabine, Methotrexate/Hydrocortisone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
- Interventions
- Blister induction, Skin Biopsies
- Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 7 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 742
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more
- Conditions
- Multiple Myeloma
- Interventions
- carfilzomib, Dexamethasone, Clarithromycin, Lenalidomide
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Iron Deficiency Anemia
- Interventions
- Ferumoxytol
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 634 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more
- Conditions
- Leukemia
- Interventions
- denileukin diftitox
- Biological
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 11
- States / cities
- Orange, California • Chicago, Illinois • Vincennes, Indiana + 8 more
- Conditions
- Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
- Interventions
- MOR00208, lenalidomide, Correlative Studies
- Biological · Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Solid Tumor
- Interventions
- ABI-010
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Myeloid Leukemia, AML
- Interventions
- Palcociclib, CPX-351
- Drug
- Lead sponsor
- Sudipto Mukherjee, MD, PhD, MPH
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- fludarabine, treosulfan, allogeneic blood or bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin
- Interventions
- ablative allogeneic hematopoietic cell transplantation
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- Siltuximab
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Dallas, Texas • Houston, Texas
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin, Plasma Cell Disorder
- Interventions
- Cyclophosphamide, Fludarabine, Total Body Irradiation, Tacrolimus, cellcept, g-csf, Peripheral Blood Transplant
- Drug · Radiation · Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Sickle Cell Disease
- Interventions
- Crovalimab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Madison, Mississippi • New York, New York + 1 more
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia
- Interventions
- amifostine trihydrate, cytarabine, idarubicin
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Idarubicin, Cytarabine, Vorinostat
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera, Essential Thrombocythemia
- Interventions
- SB1518
- Drug
- Lead sponsor
- S*BIO
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Boston, Massachusetts